# A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

> **NCT07529535** · PHASE1 · SUSPENDED · sponsor: **Zhejiang Anglikang Pharmaceutical Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Advance Solid Tumors

## Interventions

- **DRUG:** ALK-N001 for Injection

## Key facts

- **NCT ID:** NCT07529535
- **Lead sponsor:** Zhejiang Anglikang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-06-05
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Participant recruitment has been stopped because the planned sample size has been reached.
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07529535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07529535, "A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07529535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*